Business

Angelini Pharma Buys Catalyst Pharmaceuticals for $4.1B

Updated 2026-05-07 08:45 UTC 1 source Neutral

Italian firm Angelini Pharma acquired rare disease drug maker Catalyst Pharmaceuticals in a deal valued at $4.1 billion, expanding its portfolio of treatments.

Coverage timeline — 1 article

STAT News

STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B

The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.

2026-05-07 08:34 UTC